Not recruitingEUCTR 2007-002551-17
Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo i...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesBipolarity
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Belgium and 6 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 600
- Sponsor
- H. Lundbeck a/s
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-002551-17
- Official title
Show the full official title
Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo i...
Recruitment & locations
Not recruitingAustria · Belgium · France
5 more locations
- Germany
- Lithuania
- Slovakia
- Sweden
- United Kingdom
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is H. Lundbeck a/s.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ...